November 2014 | Oncology Live®

November 21, 2014

Steven Rosenberg always knew that he wanted to become a physician scientist, and he quickly advanced to become the chief of surgery at the National Cancer Institute (NCI) at just 34 years of age.

November 21, 2014

Since the modern era of anticancer immunotherapy began about four years ago, a variety of strategies to awaken the patient's own defenses against tumor cells have been reported.

November 20, 2014

Despite numerous reports of "miracle cures" for a select few patients treated with a variety of different anticancer therapies, drugs that failed to show improvement for a large number of patients have historically been considered failures and have been shelved.

November 18, 2014

When Marcela V. Maus, MD, PhD, thinks of the challenge of bringing chimeric antigen receptor (CAR) therapies to market in the battle against cancer, she is reminded of the auto industry's first days.

November 18, 2014

Confusion persists about the best choice of frontline therapy for patients with metastatic colorectal cancer (mCRC) after a landmark clinical trial that was conceived a decade ago to answer that question concluded without a superiority finding

November 12, 2014

The 5-year survival rate for patients with metastatic colorectal cancer (CRC) remains dismal.

November 12, 2014

Those of us who have treated patients with breast cancer for any extended period of time can likely share anecdotes about watching the treatment of this disease evolve to levels many of us could only have imagined when we began practicing.

November 10, 2014

Amid a coming storm of demographic trends signaling a sharp increase in the number of older people diagnosed with cancer in the United States, researchers are developing new geriatric assessment tools to help oncology specialists better manage this patient population.

November 04, 2014

As therapy options for patients with relapsed or refractory multiple myeloma have expanded in recent years, so have clinical considerations about how best to incorporate new agents into the treatment paradigm.

October 29, 2014

It is increasingly recognized that the era of treating individual advanced or metastatic cancers based essentially on the anatomic site of origin or histologic subtype as determined by light microscopic evaluation is rapidly coming to a close.

October 22, 2014

Substantial clinical trial evidence supports the use of pathologic complete response (pCR) as a measure for evaluating neoadjuvant therapies for patients with HER2-positive breast cancer, suggesting that preoperative treatment should be the standard of care

October 20, 2014

The treatment landscape for patients with chronic lymphocytic leukemia (CLL) is rapidly changing, with the emergence of four new therapeutic options for this malignancy in recent months.

October 16, 2014

At least 30 companies are seeking to develop the next generation of circulating tumor cell (CTC) technology, part of an emerging focus on analyzing the biofluids of patients with cancer as a "liquid biopsy," particularly for solid tumors.